Back to top

Analyst Blog

Shortly after announcing its fourth collaboration with Isis Pharmaceuticals (ISIS - Analyst Report), biotech company Biogen Idec (BIIB - Analyst Report) announced another deal – this time with biopharma company, Amicus Therapeutics (FOLD - Snapshot Report).

Biogen and Amicus will collaborate for the identification, development and commercialization of Parkinson’s disease treatments.

The collaboration is based on preclinical studies performed by Amicus as well as independent published research which indicate that increasing activity of the lysosomal enzyme glucocerobrosidase (GCase) in the brain may correct alpha-synuclein pathology and other deficits associated with Parkinson's disease.

Amicus’ expertise in the discovery of novel small molecules that increase GCase activity in the brain will be put to use under this multi-year collaboration for the identification of potential treatments for Parkinson’s.

Biogen, in turn, has agreed to finance all discovery, development, and commercialization activities. Biogen will also reimburse Amicus for all full-time employees involved in the project. Moreover, Biogen will make development and regulatory based milestone payments and royalties on worldwide sales.

The deal is in-line with Biogen’s efforts to expand its neurodegenerative diseases pipeline. Meanwhile, Amicus is gaining a strong development partner in the form of Biogen.

While Amicus is a Zacks Rank #3 (Hold) stock, Biogen currently carries a Zacks Rank #1 (Strong Buy). Key products, Avonex and Tysabri, should continue contributing significantly to sales. Tecfidera should help drive long-term growth. Biogen has several development and regulatory catalysts coming up in the next few quarters. With Tecfidera launched, we expect investor focus to remain on its commercialization and sales ramp up.

Other stocks that currently look well-positioned and which carry a Zacks Rank #1 include Gilead Sciences Inc. (GILD - Analyst Report).
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
LITHIA MOTO… LAD 94.15 +4.11%
DELTA AIR L… DAL 38.99 +3.48%
FLAMEL TECH… FLML 14.50 +3.42%
SOUTHWEST A… LUV 28.89 +2.99%
NUSTAR GP H… NSH 41.03 +2.32%